In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MediciNova licenses Kyorin's ibudilast for MS

Executive Summary

Kyorin has granted MediciNova exclusive worldwide rights (excluding Japan, China, Taiwan and South Korea) to develop and commercialize its ibudilast, now known as MN166, for all multiple sclerosis indications except ophthalmic solution formulations. MediciNova also gets rights to sublicense the compound.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies